Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE). Falsification or fabrication of data, plagiarism, including duplicate publication of the authors’ own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines.
All authors listed on the manuscript should have contributed significantly to the experimental design, its implementation, or analysis and interpretation of the data. All authors should have been involved in the writing of the manuscript at draft and any revision stages and should have read and approved the final version. Anyone who made major contributions to the writing of the manuscript should be listed as an author (e.g. “ghost writing” is prohibited by the Journal). Any other individuals who made less substantive contributions to the experiment or the writing of the manuscript should be listed in the acknowledgement section. Any change in authorship (including author order) after the initial manuscript submission must be approved in writing by all authors.
Authorship and “umbrella” groups
Many large collaborative studies are organized under a group name which represents all the participants. All articles must have at least one named individual as author. Authors who wish to acknowledge the umbrella group from which the data originate should first list the author(s) of the article and follow this with 'on behalf of the GROUP NAME'. If necessary the names of the participants may be listed in the Acknowledgements section.
By submitting your manuscript to the Journal it is understood that this it is an original manuscript and is unpublished work and is not under consideration elsewhere. Plagiarism, including duplicate publication of the author’s own work, in whole or in part without proper citation is not tolerated by the journal. Manuscripts submitted to the journal may be checked for originality using anti-plagiarism software
Conflicts of Interest
At the point of submission, each author should reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated – including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. When considering whether you should declare a conflicting interest or connection please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it?
As part of the online submission process, corresponding authors are required to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. If the Corresponding author is unable to confirm this information on behalf of all co-authors, the authors in question will then be required to submit a completed form to the Editorial Office. It is the Corresponding author’s responsibility to ensure that all authors adhere to this policy.
If the manuscript is published, Conflict of Interest information, including if none was declared, will be communicated in a statement in the published paper.
When reporting animal experiments authors should indicate whether the institution’s, national research council’s, or any other law on the care and use of laboratory animals was followed.
When reporting on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association. Manuscripts should include a statement that the patient’s written consent was obtained and any information, including illustrations, should be as anonymized as far as possible. Authors should indicate that the design of the work has been approved by local ethical committees or that it conforms to standards currently applied in the country of origin. The name of the authorizing body should be stated in the paper.
Patients' identities must be removed in all figures (i.e., x-rays, MRIs, charts, photographs, etc.). Written informed consent is required from any potentially identifiable patient or legal representative, and should be presented in either the Methods section or the Acknowledgements.
DEPOSITION OF SEQUENCE AND MICROARRAY DATA
Nucleotide and Protein Sequences
If a manuscript reports on any new nucleotide or protein sequences, these must be deposited in a publicly available database at the time of submission. Nucleotide sequences should be deposited in one of the three major collaborative databases – EMBL, GenBank, or DDBJ. New sequences and their accession numbers should be listed at the beginning of the Methods section. Protein sequences should be deposited with UniProt.
Authors submitting microarray data should comply with the “Minimal Information About a Microarray Experiment” (MIAME) guidelines. Microarray data should also be submitted to GEO (www.ncbi.nlm.nih.gov/geo/) or ArrayExpress (www.ebi.ac.uk/arrayexpress) and to provide accession numbers by the time the paper is accepted.
Registering Clinical Trials
In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (ICMJE) all clinical trials published in the journal must be registered in a public trials registry at or before the onset of participant enrolment. For any clinical trials commencing prior to 2008, retrospective registration will be accepted.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, managed by a not-for-profit organization, and include all the necessary information as specified by the ICMJE. A list of recommended registries can be found on the ICMJE website. Results posted in the same clinical trials registry in which the primary registration resides will not be considered prior publication if they are presented in the form of a brief abstract (<500 words or less) or a table.
Authors are requested to provide the exact URL and unique identification number for the trial registration at the time of submission. This information will be published in the article and we ask that you include the URL and identification number on the title page of your manuscript
Reporting clinical trials
Clinical trials should comply with the Consolidated Standards of Reporting Trials Statement (CONSORT), which is available here. Authors reporting on randomized clinical trials (RCT) should consult the CONSORT checklist when preparing their manuscripts. All RCT data will be evaluated in accordance with the rules and checklist of the CONSORT statement.
Other types of studies should follow guidelines where available. These include STARD (Standards for the Reporting of Diagnostic accuracy studies), STROBE (Strengthening the reporting of observational studies in epidemiology), PRISMA (Transparent Reporting of Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analyses of observational studies). For further information on good reporting of health research studies please go to the EQUATOR network.
The mention of trade names, commercial products or organizations, and the inclusion of advertisements in OFID does not imply endorsement by the society, the editors, the editorial board, OUP, or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in OFID. The ultimate responsibility for the use and dosage of drugs mentioned in OFID and in the interpretation of published material lies with the medical practitioner, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in OFID. Please inform the editors of any errors.
The opinions expressed in OFID are those of the authors and contributors, and do not necessarily reflect those of the society the editors, the editorial board, OUP, or the organization to which the authors are affiliated.
LANGUAGE EDITING PRE-SUBMISSION
If your first language is not English, language editing is optional to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Language editing does not guarantee that your manuscript will be accepted for publication. For further information on this service, please click here. Several specialist language editing companies offer similar services and you can also use any of these. Authors are liable for all costs associated with such services.
OFID publishes original, de novo submissions, as well as submissions cascaded from Clinical Infectious Diseasesand The Journal of Infectious Diseases. De novo submissions include both invited and uninvited manuscripts that were not previously submitted to CID or JID prior to submission to OFID. The cascade approach refers to manuscripts originally submitted to CID or JID, which the CID or JID team did not accept for publication, either prior to or following a full peer review.
All de novo submissions to the journal are initially reviewed by the Editor and Associate Editors. At this stage manuscripts may be rejected without peer review if it is felt that they are not of high enough priority or not relevant to the journal. This fast rejection process means that authors are given a quick decision and do not need to wait for the review process. De novo submissions that are not instantly rejected are sent out for peer review, usually to two independent reviewers. Based on the feedback from these reviewers and the judgment of the editorial team, a decision is given on the manuscript. Manuscripts may also be sent out for statistical review.
Manuscripts rejected following peer review by CID or JID are encouraged to have their manuscript redirected to OFID with the earlier reviews, which will facilitate a faster publication process. These manuscripts may be sent out for additional peer review, and based on the feedback from all of the reviewers and the judgment of the editorial team, a decision is given on the manuscript.
In addition, Fellows of the Infectious Diseases Society of America (FIDSA) may submit one manuscript per year via a privileged track, which will facilitate a faster publication process. The Fellow must be an author of the paper, and the Fellow will select his/her own reviewers, revise the manuscript based on the reviewers’ comments, and then submit the revised manuscript with the reviews to the editorial office. These manuscripts may be sent out for additional peer review, and based on the feedback from all of the reviewers and the judgment of the editorial team, a decision is given on the manuscript.
If you believe that your manuscript has been incorrectly rejected by the editorial team, authors may send an appeal to the editorial office. To submit an appeal please send an email to the editorial office giving as much detail as possible about why you believe that your manuscript has been incorrectly rejected. Please do not re-submit your article.
Authors may appeal an Editor’s decision if they think it is unwarranted. Appeals must be submitted by email to the editorial office, and provide as much detail as possible about why the manuscript should be reconsidered. Please do not resubmit your article.
Occasionally the journal will issue press releases for some of its articles. Authors submitting to the journal are expected to respect any press embargos set for their manuscript.
- Instructions to Authors
- ICMJE Form
- Submit Now!
- OUP Services for Authors
- Rights & Permissions
- Self-archiving Policy